MedTech Europe urges tariff relief as EU–US deal leaves medical technologies exposed

Posted on 05.08.2025

MedTech Europe welcomes the progress made in the recent agreement between the United States and the European Union on trade relations, averting the worst-case scenario. However, we remain deeply concerned that the 15% tariff rate may be applicable to certain European medical technology exports to the US, as per the Executive Order of 31 July 2025.

Ensuring tariff-free transatlantic trade for medical technologies is critical, not only for the economy and competitiveness, but for patients, the provision of healthcare on both sides of the Atlantic and leadership in health innovation.

“Patients must not bear the cost of trade tensions. Medical technologies are fundamental to delivering care and saving lives,” said Oliver Bisazza, CEO of MedTech Europe. “Leaving them burdened by tariffs undermines healthcare systems, slows innovation, and ultimately impacts patients. We need to go further. The zero for zero solution is urgent.”

We are currently assessing the implications of the EU–US agreement for our sector, and awaiting further details. MedTech Europe calls on policymakers to maintain momentum in negotiations and develop a dedicated bilateral solution that fully eliminates tariffs on medical technologies and their essential components.

Download our statement below.